MedTrace Logo

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

NCT00740064 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-01-28

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Raltegravir and Epzicom over 48 weeks in ART-naive HIV-infected subjects.

Conditions

  • HIV Infections

Interventions

DRUG

Raltegravir and Abacavir/Lamivudine

Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Denver Infectious Disease Consultants, PLLC

    lead OTHER

Principal Investigators

  • Benjamin Young, MD, PhD · Denver Infectious Disease Consultants, PLLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-08-31
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740064 on ClinicalTrials.gov